Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04398134 · ClinicalTrials.gov registry record · Phase 2
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
A Phase 2 study, sponsored by Assembly Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT04398134: Clinical Trial Phase 2 study, sponsored by Assembly Biosciences.
NCT04398134 is a Phase 2 study that was terminated before completion, run by Assembly Biosciences. The registered enrollment target is 88 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04398134, a Phase 2 study, was terminated before completion, sponsored by Assembly Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus (HBV) infection.
Primary Outcome
Describes the number of participants with One or More Adverse Events while they were on treatment with the study drug.
Interventions
- DRUG Placebo
- DRUG Entecavir (ETV)
- DRUG ABI-H2158
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2021-12-28 |
| Phase | Phase 2 |
Why NCT04398134 stopped before completion
NCT04398134 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04398134 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04398134 about?
NCT04398134 is a clinical study titled "A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection". This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus (HBV) infection.
What is the current status of trial NCT04398134?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2020-08-28. Estimated completion is 2021-12-28.
What interventions are being tested in trial NCT04398134?
The interventions under investigation include: Placebo (DRUG), Entecavir (ETV) (DRUG), ABI-H2158 (DRUG).
Who is sponsoring clinical trial NCT04398134?
This trial is sponsored by Assembly Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04398134's enrollment target sits among peer trials
88 803rd of 2000 higher than 1,191 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI